No Detail Found!

Applicability Magnitude of Clinical Practice Guidelines for Osteoporosis among Orthopedician's Practice: a Cross Sectional Study.

Author(s)
Sheikh Abdul Khaliq Hamdard University, Karachi, Pakistan
Syed Baqir Shyum Naqvi Hamdard University, Karachi, Pakistan
Anab Fatima Dow University of Health Sciences (DUHS), Karachi, Pakistan
Bilqees Fatima Hamdard University, Karachi, Pakistan
Abstract
OBJECTIVE: To evaluate the magnitude of applicability of International Osteoporosis Foundation Guidelines for diagnosis, prevention and treatment of Osteoporosis in Pakistan. STUDY DESIGN: A Prospective cross sectional study PLACE AND DURATION: From December 1st, 2015 to January 31st, 2017 at hamdard University. METHODOLOGY: Primary data has been collected from 90 orthopedic surgeons. Six main domains provided by AGREE - II instrument were evaluated include scope and purpose, stakeholder involvement, rigour of development, clarity of presentation, applicability, editorial independence and overall quality of International Osteoporosis Foundation Guideline. RESULTS: Number of orthopedic surgeons from hospital and clinics are 97% and 3% respectively. Magnitudes of six domains were found to be 72% for scope and purpose, 70% for stakeholder involvement, 78% for rigour of development, 91% for clarity of presentation, 87% for applicability, and 74% for editorial independence, all these domains are significantly (p<0.002) lower compares to ideal score. 42.22% orthopedicians are interested to use guidelines without any changes. 55.56% suggested the need to change guidelines, while 2.22% did not show interest to practice these guidelines. CONCLUSION: Examination of the overall assessment of guideline by the appraisers revealed that majority of orthopedicians did not reject the guideline.
Publication Details
Page(s) 229-232
DOI DOI not available
Published Journal: Isra Medical Journal, Volume: 9, Issue: 4, Year: 2017

Request the full text from PASTIC

References
FieldMJ,LohrKN., 1990.Clinical practice guidelines: directions for a new program, 1 -56
BrouwersMC,KhoME,BrowmanGP,BurgersJS,CluzeauF,FederG, 2010.AGREE II: advancing guideline development, reporting and evaluation in health care,Can Med Asso J 182 839 -42
RiazS,AlamM,UmerM., 2006.Frequency of osteomalacia in elderly patients with hip fractures,J Pak Med Asso 56 273 -76
HarinarayanC,Natl Med, 2004.What's in a name-25 (OH) D or 25 (OH) D3, 17 114 -15
HamiltonBE,MartinJA,VenturaSJ, 2010.Births: Preliminary data for 2008, 58 1 -18
BrouwersMC,KhoME,BrowmanGP,BurgersJS,CluzeauF,FederG, 2010.Development of the AGREE II, part 2: assessment of validity of items and tools to support application,Cana Med Assoc J 182 472 -78
BrouwersMC,KhoME,BrowmanGP,BurgersJS,CluzeauF,FederG, 2010.Development of the AGREE II, part 1: performance, usefulness and areas for improvement,Can Med Asso J 182 1045 -52
LauE,SambrookP,SeemanE,LeongK,LeungP,DelmasP, 2006.Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia,Aplar J of Rheu 9 24 -36
FaulF,ErdfelderE,LangAG,BuchnerAG, 2007.Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences,Beh Res Meth 39 175 -91
BrouwersMC,BrowmanG,BurgersDJ,CluzeauF,DavisD,FederG, 2009.Appraisal of guidelines for research & evaluation (AGREE - II) instrument -, 1 -11
WoolfS,SchünemannHJ,EcclesMP,GrimshawJM, 2012.Developing clinical practice guidelines: types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendations,Implementation Sci 7 61 -
GardnerB,DavidsonR,McAteerJ,MichieS., 2009.A method for studying decision-making by guideline development groups,Implementation Sci 4 48 -
SteinbergE,GreenfieldS,WolmanDM,MancherM,GrahamR., 2011.Clinical practice guidelines we can trust, -
QaseemA,ForlandF,MacbethF,OllenschlägerG,PhillipsS,van der Wees P. Guidelines International, 2012.Network: toward international standards for clinical practice guidelines,Ann of Int Med 156 525 -31
Als-NielsenB,ChenW,GluudC,KjaergardLL, 2003.Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?,The J of the Am Med Asso 290 921 -28
LexchinJ,BeroLA,DjulbegovicB,ClarkO, 2003.Pharmaceutical industry sponsorship and research outcome and quality: systematic review,Bol Med 326 1167 -70
DetskyAS, 2006.Sources of bias for authors of clinical practice guidelines,Can Med Asso J 175 1033 -
ShaneyfeltTM,CentorRM, 2009.Reassessment of clinical practice guidelines: go gently into that good night,The J of the Ame Med Asso 301 868 -69
SnidermanAD,FurbergCD, 2009.Why guideline-making requires reform,The J of the Ame Med Asso 301 429 -31
EcclesMP,GrimshawJM,ShekelleP,SchünemannHJ,WoolfS. Developing, 2012.clinical practice guidelines: target audiences, identifying topics for guidelines, guideline group composition and functioning and conflicts of interest,Implementation Sci 7 60 -
BoydEA,BeroLA, 2000.Assessing faculty financial relationships with industry: a case study,The J of the Ame Med Asso 284 2209 -14
CampbellEG, 2007.Doctors and drug companies-scrutinizing i nf l u e nt i a l re l at i o n s h i ps . N ew E n g J o f M e d, 357 1796 -97
JacobsAK,LindsayBD,BellandeBJ,FonarowGC,NishimuraRA,ShahPM, 2004.Task force 3: Disclosure of relationships with commercial interests: policy for educational activities and publications,Circulation 110 2524 -28
0

Citations

0

Downloads

60

Views